Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on Tovecimig

2 evidence topics · 2 sources

Protocol restrictions on anticoagulants, antiplatelet agents, and prior anticancer therapy

“Current or recent (within 10 days prior to study treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose will be excluded” (opens the source at this quote in a new tab)

“Patients with current or recent (within 10 days of study treatment) use of aspirin (>81 mg/day), or other NSAIDs, or other antiplatelets (i.e., dipyridamole, ticlopidine, clopidogrel and cilostazol) will be excluded” (opens the source at this quote in a new tab)

“Less than 2 weeks have elapsed since patients had chemotherapy or hormone therapy” (opens the source at this quote in a new tab)

Covariates tested in the population pharmacokinetic analysis

“Except for body weight, no other covariate was determined as significant to the PK properties of ABL001/CTX‐009, and the body weight was assessed as a significant covariate for V1 by leading to the largest decrease in the OFV and was added as a covariate on V1 as below:” (opens the source at this quote in a new tab)

Dedicated clinical drug interaction studies

No evidence found.